The firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug. In early afternoon trade in London the company share price was down 1% at 1218 pence. Glaxo is relying on new treatments for conditions such as cancer, diabetes, depression, HIV/AIDS and allergies to lift the pace of sales growth after several disappointing years. "The continuing success of our key products means we can now look forward to a good performance in 2005," he said.